Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients

The DR-70® (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared for 113 CRC monitoring patients. Tota...

Descripción completa

Detalles Bibliográficos
Autores principales: Small-Howard, Andrea L., Harris, Holden
Formato: Texto
Lenguaje:English
Publicado: Taylor & Francis 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872273/
https://www.ncbi.nlm.nih.gov/pubmed/20391025
http://dx.doi.org/10.1080/15321811003617438
_version_ 1782181203140411392
author Small-Howard, Andrea L.
Harris, Holden
author_facet Small-Howard, Andrea L.
Harris, Holden
author_sort Small-Howard, Andrea L.
collection PubMed
description The DR-70® (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared for 113 CRC monitoring patients. Total concordance rates for DR-70 and CEA were 0.665 and 0.686, respectively. CRC patient pairs were grouped based on their CEA value to deduce DR-70's effectiveness at monitoring patients with low CEA values. DR-70 had 12% to 100% greater positive concordance rates than CEA in this group. DR-70 is a welcome new option for CRC patients.
format Text
id pubmed-2872273
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-28722732010-05-18 Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients Small-Howard, Andrea L. Harris, Holden J Immunoassay Immunochem Article The DR-70® (FDP) test was the first cancer test cleared by USFDA for monitoring colorectal cancer (CRC) since Carcinoembryonic Antigen (CEA) in 1982. Conservatively, 50% of biopsy-positive CRC patients have negative CEA values. DR-70 and CEA values were compared for 113 CRC monitoring patients. Total concordance rates for DR-70 and CEA were 0.665 and 0.686, respectively. CRC patient pairs were grouped based on their CEA value to deduce DR-70's effectiveness at monitoring patients with low CEA values. DR-70 had 12% to 100% greater positive concordance rates than CEA in this group. DR-70 is a welcome new option for CRC patients. Taylor & Francis 2010-03-23 2010-04 /pmc/articles/PMC2872273/ /pubmed/20391025 http://dx.doi.org/10.1080/15321811003617438 Text en © 2010 AMDL Diagnostics, Inc. http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf This is an open access article distributed under the Supplemental Terms and Conditions for iOpenAccess articles published in Taylor & Francis journals (http://www.informaworld.com/mpp/uploads/iopenaccess_tcs.pdf) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Article
Small-Howard, Andrea L.
Harris, Holden
Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients
title Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients
title_full Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients
title_fullStr Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients
title_full_unstemmed Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients
title_short Advantages of the AMDL-ELISA DR-70 (FDP) Assay over Carcinoembryonic Antigen (CEA) for Monitoring Colorectal Cancer Patients
title_sort advantages of the amdl-elisa dr-70 (fdp) assay over carcinoembryonic antigen (cea) for monitoring colorectal cancer patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2872273/
https://www.ncbi.nlm.nih.gov/pubmed/20391025
http://dx.doi.org/10.1080/15321811003617438
work_keys_str_mv AT smallhowardandreal advantagesoftheamdlelisadr70fdpassayovercarcinoembryonicantigenceaformonitoringcolorectalcancerpatients
AT harrisholden advantagesoftheamdlelisadr70fdpassayovercarcinoembryonicantigenceaformonitoringcolorectalcancerpatients

Ejemplares similares